UPSTO Extends Pilot Programs

03 October 2022 PharmaPatents Blog
Author(s): Courtenay C. Brinckerhoff

October marks the start of a new fiscal year for the USPTO. Last week the agency announced the extension of several pilot programs that will continue on into 2023 and beyond.


The Cancer Immunotherapy Pilot Program

The Cancer Immunotherapy Pilot Program (also referred to as the Patents 4 Patients program) has been extend through January 31, 2023. This program is intended to support the Cancer Moonshot initiative and promote innovation in cancer treatments by offering fee-free expedited examination of patent applications claiming methods of treating cancer using immunotherapy. In announcing the extension, the USPTO reported that so far over 650 patents have been granted under the pilot program.

Other subject-matter specific expedited examination programs include the Climate Change Mitigation Pilot Program (for innovations that reduce greenhouse gas emissions) set to expire June 5, 2023, and the Covid-19 Prioritized Examination Pilot Program (open only to applications with Small Entity or Micro Entity status) set to expire December 31, 2022.

The After Final Consideration Pilot Program 2.0

The After Final Consideration Pilot (AFCP) Program 2.0 has been extended to September 30, 2023. As explained on the USPTO’s AFCP 2.0 webpage, the program “authorizes additional time for examiners to search and/or consider responses after final rejection.” As noted in this article, AFCP 2.0 is intended to “reduc[e] the number of Requests for Continued Examination (RCE) and encourage[e] increased collaboration between the applicant and the examiner to effectively advance the prosecution of the application.” 

Since the program was rolled out in May 2013, many stakeholders wonder how it is still a “pilot” program, and whether it has been successful.

The Fast-Track (Ex Parte) Appeals Pilot Program

The Fast-Track Appeals Pilot Program has been extended through July 2, 2024. As explained in this article, this program offers applicants an opportunity to expedite Board review of ex parte appeals of an examiner’s rejection, for a fee of $400. In announcing the extension, the USPTO reported that “the current average appeal pendency is about 12 months, down from 15 months in 2020, and 30 months in 2015.” The announcement seems to encourage applicants to consider appealing final rejections instead of continuing prosecution, stating that “[u]sing the appeal process may be more expeditious for inventors and may speed the ultimate issuance of patents as opposed to request for continued examination practice.”

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services


2023 M&A Outlook
05 December 2022
Foley Ignite
COVID-related Form I-9 Remote Verification Flexibilities Extended Through July 31, 2023
05 December 2022
Labor & Employment Law Perspectives
Learnings from Recent Physician Practice Private Equity Transactions
05 December 2022
Health Care Law Today
Get up to Speed: Blockchain for the Auto Industry
05 December 2022
Dashboard Insights
What You Should Know About Payor/Provider Convergence
25-26 January 2023
Los Angeles, CA
ATA EDGE2022 Policy Conference | American Telemedicine Association
7-9 December 2022
Washington, D.C.
CLE Weeks
5-16 December 2022
Milwaukee, WI
Foley Sponsors Ernst & Young Entrepreneur of the Year® Program
1 December 2021 - 30 November 2022
Michigan and Northwest Ohio Region